Tremendous excitement has been generated by the use of botulinum toxin for the treatment of various types of urethral and bladder dysfunction over the past several years. Botulinum toxin is the most lethal naturally occurring toxin known to mankind. Why, then, would an urologist want to use this agent to poison the bladder or urethral sphincter? In this review article we will examine the mechanisms underlying the effects of botulinum toxin treatment. We will discuss the current use of this agent within the urologic community and will provide perspectives on future targets of botulinum toxin.

**Key words:** Botulinum toxin, urethra, bladder

The world's most potent biological toxin, botulinum toxin, was first isolated in 1897 by van Ermengem [1]. The toxin acts by inhibiting acetylcholine release at the presynaptic cholinergic junction. In the late 1980s the urologic community began to explore the use of botulinum toxin type A (BTX-A) to treat spinal cord injured patients suffering from detrusor external sphincter dyssynergia (DESD) [2-4]. A resurgence of interest over the past 5 years was led by Schuch and colleagues who reported successful treatment of spinal cord injured patients with detrusor hyperreflexia using intravesical BTX-A injections at multiple sites [5].

**History of Botulinum Toxin's Medical Development**

*What is the story of how this “food poison” became a useful medical drug?* Botulinum poisoning was first described in cases of sausage poisoning in the late 1700s in Germany. A local medical officer collected data on 230 cases of botulism, and the illness became known as “Kerner’s disease” [6]. It wasn’t until 1897 that van Ermengem isolated the spore-forming obligate anaerobic bacteria, *Clostridium botulinum* [1].

*How does botulinum toxin cause paralysis?* Botulinum toxins are synthesized as single chain polypeptides with a molecular weight of approximately 150 kilodaltons (kDa) [7]. Initially, the parent chain is cleaved into its active, dichain polypeptide form consisting of a heavy chain (approx. 100 kDa) connected by a disulfide bond to a light chain (approx. 50 kDa) with an associated zinc atom (Fig. 1) [8]. Three steps are required for toxin induced paralysis: 1. binding and internalization of the toxin within the nerve terminal; 2. translocation of the light chain into the cytosol; and 3. inhibition of neurotransmitter release.

Acetylcholine release involves the ATP-dependent
transport of the vesicle from the cytosol to the plasma membrane [9]. Vesicle docking requires the interaction of various cytoplasmic, vesicle, and target membrane proteins, some of which are specifically targeted with clostridial neurotoxins. BTX-A, for example, cleaves the cytosolic translocation protein SNAP-25, thus preventing vesicle fusion with the plasma membrane (Fig. 2) [10].

**Different Applications of Botulinum Toxin**

Seven immunologically distinct neurotoxin types are known and are typically labeled from A-G. BTX-A (Botox®, Allergan Irvine, CA, USA) received FDA approval in 1989 for the treatment of strabismus, benign essential blepharospasm, and disorders of the VIIth nerve. Since its introduction into clinical use in the 1980s, BTX-A has been successfully used to treat various conditions, including blepharospasm, strabismus, focal dystonias, muscle spasms and spasticity, axillary hyperhidrosis, and achalasia [11-15]. More recently, the U.S. FDA approved a BTX-B complex preparation (Myobloc™, Elan South San Francisco, CA, USA) for clinical use in cervical dystonia patients.

**Botulinum Toxin’s Urologic Applications**

**Sphincter Application.** Urological applications of BTX-A have been primarily associated with cases of Detrusor External Sphincter Dyssynergia (DESD). Management of spinal cord injured (SCI) patients was revolutionized with the development of clean intermittent
catheterization (CIC) by Lapides in 1971 [16]. However, not all patients can tolerate CIC and require an alternative that decreases outlet resistance and allows continuous bladder decompression. Various alternatives have been described, including external sphincterotomy, radical TURP, and various denervation procedures, i.e. dorsal rhizotomy [17]. These procedures are unfortunately permanent and irreversible, and carry with them inherent risks (i.e. bleeding, stricture formation, fistulas).

BTX-A represents a viable option in the treatment of DESD. The toxin acts at the neuromuscular junction of the external sphincter to block vesicle transport of acetylcholine, in essence producing chemical denervation. The clinical effects begin within 2-3 days and are reversible as terminal nerve sprouting occurs within 3-6 months [18]. Injection of BoNT/A (i.e. BoNT = laboratory grade botulinum toxin) into the sternomastoid muscle of mice has been shown to induce the formation of terminal nerve sprouts from the parent terminal [19]. The sprouts form functional synapses with the muscle but eventually regress at a time when the parent nerve terminal regains the ability to release neurotransmitters. It remains to be seen whether similar processes occur in autonomic nerves innervating the lower urinary tract.

Dykstra has investigated the effects of BTX-A injection in 2 studies of SCI patients with DESD. In the first study, published in 1988, all 10 patients evaluated by electromyography after injection showed signs of sphincter denervation [4]. The urethral pressure profile decreased by an average of 27 cm of water, and post void residuals decreased by an average of 146 cc after toxin injection. In 1990, Dykstra reported the results of the only double-blind placebo controlled study of BTX-A injection into the external urethral sphincter of 5 men with SCI and DESD [3]. Electromyography of the external urethral sphincter indicated denervation in the 3 patients who received toxin injections. The urethral pressure profile decreased by an average of 25 cm/H₂O; the post void residual decreased by an average of 125 ml; and bladder pressure during voiding decreased to an average of 30 cm/H₂O. Parameters were unchanged from baseline in the 2 patients who received normal saline injections.

We performed a prospective study on 21 patients referred to our clinic with voiding dysfunction [20]. All patients were evaluated with video-urodynamics. Follow-up ranged from 3-16 months. Following urethral injection of Botox®, voiding pressures decreased by an average of 38%. Sixty-seven percent of patients reported an improvement in voiding patterns. No complications or side effects were noted. Our results are consistent with the largest series to date treating DESD with BTX-A. In that study, Schurch treated 24 patients with SCI and DESD with BTX-A injection [21]. Significant improvement in DESD was noted in 21/24 pts (88%) with decreased post void residuals in most patients. The effects lasted 3-9 months with no adverse events reported. Thus, BTX-A toxin injections appear to be a safe and efficacious treatment option for DESD.

The clinical success of BTX-A is supported by laboratory research demonstrating marked decreases in the release of labeled norepinephrine and acetylcholine in BoNT/A injected rat urethral sphincters [22]. While the therapeutic effects of inhibiting acetylcholine release are obvious, blockage of norepinephrine release may also provide clinical benefits by inhibiting sympathetic transmission and smooth muscle dysynergia in the urethra. These results suggest that the therapeutic effect depends on both somatic and autonomic nerves.

In addition to classic neuropathic DESD, we have expanded the indications for use of botulinum A toxin to include patients with a variety of bladder outlet obstructions, excluding those patients with obstructions secondary to fibrosis. We have successfully used botulinum A
toxin to treat voiding dysfunction in multiple sclerosis patients with DESD, patients with pelvic floor spasticity, and even in an acontractile multiple sclerosis patient who wished to void by valsala [20]. Recently, we reported a case of functional urethral obstruction and detrusor acontractility following pubovaginal sling surgery that was successfully treated by botulinum A toxin urethral sphincter injection [23].

We perform Botox® urethral sphincter injections by mixing one vial (100 units) of Botox® with 10 cc of saline just prior to injection. It is important not to shake the vial, as this may break the disulfide linkage between the light and heavy chains and render the toxin ineffective. Using a collagen injection needle (we prefer Cook® because of the sharper end), injections of 2.5 cc each are made at the 12, 3, 6, and 9 o’clock positions at the level of the striated sphincter. Injections must be directed deeper than collagen injections in order to target nerve terminals innervating skeletal muscle. We also flush the needle with 0.2 cc of saline at the end of the procedure to ensure that no toxin is wasted.

**Bladder Application.** Data have been accumulating on the clinical application of BTX-A to detrusor muscle in hyperreflexic bladders of spinal cord injured patients. A preliminary study by Schurch and colleagues in 31 patients with detrusor hyperreflexia demonstrated a significant increase in mean maximum bladder capacity (296 ml to 480 ml, $P < 0.016$) and a significant decrease in mean maximum detrusor voiding pressure (65 to 35 cm H$_2$O, $P < 0.016$) in patients injected with BTX-A [5]. A follow-up, long-term study completed by the same investigators in 87 patients with detrusor hyperreflexia corroborated the efficacy of intravesical botulinum toxin injection found in their earlier study [24]. In addition, they reported clinical responses lasting 4–14 months and observed no adverse effects with treatment. Detrusor muscle injections were performed in over 30 sites with either 300 units of Botox® or 500–750 units of Dysport®. The trigone was spared, presumably, to avoid the potential complication of vesicoureteral reflux.

In contrast, Del Popolo noted hyposthenia in 5/61 patients treated with high-dose intravesical BTX-A injections (300u of Botox® or 1000u Dysport®) [25]. The suprapresional weakness was transient in nature, disappearing 2–4 weeks after injection, and was abolished with lower dosage injections (500u Dysport®). Clearly, the dose and volume injected play a significant role in inducing systemic toxicity with BTX-A. Multiple injections of lower doses would be expected to have a more localized and less systemic effect. However, the primary disadvantage of intravesical BTX-A injections for many urologists is the repeated cystoscopy and toxin injections that are necessary to maintain clinical results.

BTX-A injections have extended beyond the realm of neurogenic bladders to patients with non neurogenic voiding and storage disorders. Radziszewski and associates reported favorably on the effects of intravesical BTX-A injections in a pilot study of patients with either idiopathic bladder overactivity or functional outlet obstruction [26]. Following intravesical or sphincteric BTX-A injections, patients demonstrated a resolution of incontinence and improved voiding efficiency, respectively. Finally, Zermann and colleagues presented their experience with intravesical BTX-A injection in seven patients with severe urgency-frequency-syndrome refractory to anticholinergic therapy or electrical stimulation [27]. In contrast to other studies involving intravesical BTX-A injections, the authors targeted the trigone and bladder base with 5–7 injections of 50, 100, or 200 units of Botox®. Four of seven patients responded to treatment with decreases in frequency and increased bladder capacity. No mention was made of vesicoureteral reflux as a complication of treatment.

We recently presented a single surgeon’s experience using Botox® in the bladder and urethra in 50 patients for a variety of dysfunctions over the past 3 years [28]. Between October of 1998 and October 2001, 50 patients (age range 31–84) were injected with botulinum toxin into the bladder (n = 10) or urethra (n = 40). Of these, 19 were men and 31 were women. Voiding dysfunctions were a result of both neurogenic and non neurogenic conditions and included: multiple sclerosis, spinal cord injury, cerebral vascular accident, overactive bladder, interstitial cystitis, and dysfunctional voiding. Procedures were performed using light sedation. Patients were treated with either 100 units of Botox® divided in equal doses into the 4 quadrants of the external sphincter, or via injection into the bladder base using 100–300 units of botulinum toxin diluted in 20 ml of sterile saline. Presently, 15 of these patients have undergone further injections (as many as 4) at intervals of 6 months or more.

Maximal efficacy of botulinum injection was achieved within 7 days post injection. Analysis of the 50 patients indicates that 41 of 50 patients (82%) reported a decrease or absence of incontinence as well as a significant decrease in voiding symptoms. Sleep quality and quality in-
creased in more than 50% of patients. Follow-up of these patients indicates that effects lasted up to 12 months. No patient developed stress incontinence or urinary retention.

These latest clinical findings are supported by research of ours and others demonstrating the efficacy of BoNTs on autonomic nerves [29-32]. Our study results indicate that the release of norepinephrine and acetylcholine was reduced by 60% and 64%, respectively in BoNT/A-treated versus control rat bladders [32].

Research Development

**Botulinum Toxin Isoforms.** An interesting side effect of patients with cervical dystonia injected with BTX-B (Myobloc™, Elan) is the development of dry mouth [33]. In a rare occurrence following BTX-A treatment, dry mouth was unexpected because the salivary glands were farther from the injection site than relatively unaffected lingual or lower facial muscles. This effect indicates that BTX-B may have a greater affinity for cholinergic nerves innervating the salivary glands rather than lingual or lower facial muscles or, alternatively, that there are more BTX-B receptors in salivary glands compared to muscles of the lower face and tongue. Future studies should clarify whether similar effects can be seen in parasympathetic cholinergic nerves innervating the lower urinary tract.

In addition, evidence from Carpenter’s experiments in the late 1960s as well as that from our lab suggests that rat bladders are significantly more sensitive to the effects of BoNT/D than BoNT/A [29, 34]. In fact, Carpenter has found that parasympathetic blockade with BoNT/D occurs before somatic neuromuscular blockade. It remains to be seen whether these effects are merely due to differing sensitivities of various cholinergic nerve endings to different toxins, or whether BoNT/D’s greater efficacy in the bladder is due to an effect on non-cholinergic transmission. Currently, no data exist regarding whether these same differences in rat bladder sensitivity to toxin isoforms exist in the human bladder.

**Afferent Nerve Effects.** Several investigators have demonstrated in vitro evidence of an afferent effect of botulinum toxin. Welch and colleagues have reported that neuropeptide release from rat dorsal root ganglia is inhibited by botulinum toxin (BoNT/A, B, C1, F) treatment, while Purkiss and colleagues have noted that incubation of rat dorsal root ganglia with BoNT/A inhibits the release of radioactively labeled glutamate [35, 36]. The inhibition of transmitter release from nociceptive neurons could impair mechanisms involved with central sensitization and could position botulinum toxin as a therapeutic agent in conditions such as chronic pain.

Current in vivo studies support a role for BTX-A in relieving nociceptive pain. In a model of pain associated with formalin-induced inflammation, rats were pretreated in the hind paw with BTX-A prior to injection with formalin [37]. Formalin provokes pain via a direct stimulation of nociceptors (Phase I) and, subsequently, by inflammation (Phase II). Formalin was injected 5 and 12 days after BTX-A injection. Surrogate markers of pain included paw-licking and paw-lifting behavior. Pretreatment with BTX-A significantly reduced pain at 5 and 12 days post injection. These results support clinical observations that BTX-A has an antinociceptive effect that is independent of its effects on the neuromuscular junction.

We have preliminary results suggesting that BoNT/A treatment inhibits afferent nerve mediated bladder strip contractions, presumably by blocking neurotransmitter release from peripheral afferent nerve terminals in the bladder [38]. BoNT/A treatment was found to significantly decrease afferent nerve-mediated contractions in response to both electrical and chemical stimulation by 44.6% and 35.1%, respectively, compared to saline-treated animals ($P < 0.05$).

In addition, we have clinical experience with Botox® treatment in a 42-year-old female patient suffering from recalcitrant IC (personal observation). Under light sedation, following hydrodistension with saline (80 cm) for 5 min, 100 units of Botox®, diluted in 100 ml of saline, was instilled in the bladder and held for 30 min. The patient was discharged home the same day and followed up over the ensuing 6 months. One week following Botox® treatment, the patient noted a marked improvement in her voiding symptoms, characterized by decreased frequency, urgency, and urge incontinence episodes. Nocturia decreased four fold, and painful bladder symptoms diminished greatly as evidenced by a 50% decrease in oral pain medication usage. On a visual analog scale, the patient’s bother score decreased from a 10 to a 5 following BTX-A treatment. Maximal therapeutic effects lasted 3 months, with some improvement still noted at 6 months post treatment. Our preliminary findings may lead to new therapeutic applications of BTX-A such as treating conditions associated with increased afferent nerve excitability (i.e. spinal cord injury,
chronic inflammation).

Clearly, BTX-A has a much wider spectrum of application within the urologic field than merely the treatment of DH and DESD in SCI patients. Treatment should be extended to other fields, including the MS population and those with non neurogenic voiding and storage disorders. Our basic research evidence that BoNT/A inhibits norepinephrine release in the rat bladder and urethra should prompt studies investigating the effects of botulinum toxin on disorders of increased sympathetic activity (e.g. functional bladder neck obstruction, detrusor internal sphincter dysynergia, and BPH). Finally, if afferent nerve transmission is impaired by botulinum toxin, a significant patient population will be opened up to this treatment (Fig. 3).

Conclusions

Since the 1980s, injection of botulinum toxin has proven to be a safe and effective therapy for a variety of somatic and autonomic motor disorders. Urologists are now finding clinical success with urethral and bladder BTX-A injections in the treatment of detrusor-sphincter dysynergia, non neurogenic pelvic floor spasticity, and refractory overactive bladder. Many interesting research questions remain regarding BTX’s effects on the neural pathways of the lower urinary tract [39]. However, one cannot deny the ingenuity of man in transforming the lethal toxin of *Clostridium botulinum* into a modern-day therapeutic medicine.

References


